img

News Topical, Digital Desk : Cipla Ltd has given a big update as soon as the stock market closed on Thursday. The company said that Eli Lilly and Cipla have entered into a marketing and distribution agreement for launching Yurpeak, the second brand of Tirzepatide in India. In the information given to the exchange, the company said that Eli Lilly and Company (India) Pvt. Ltd and Cipla Limited have entered into a strategic agreement for the distribution and marketing of Yurpeak, the second brand of Tirzepatide medicine in India. Under this partnership, Cipla will get the rights to distribute and promote Yurpeak in India.

The company stated that this initiative aims to expand the drug's reach nationwide and reach more patients beyond Lilly's existing presence. Under this agreement, Lilly will produce and supply Yurpeak, while its price will remain the same as Lilly's existing brand, Mounjaro. 

Share Performance: The company's shares closed at ₹1,645 on Thursday, down 1.12%. Over the past year, the company's stock has gained 10.73%. 


Read More: Russia Stock Market Crash: New US-European sanctions cause panic in Russia! Stock market and currency ruble fall sharply.

--Advertisement--

eli lilly Cipla Yurpeak Tirzepatide Mounjaro type 2 diabetes Obesity Treatment pharma partnership drug launch India Lilly India Cipla agreement chronic diseases innovative medicines Winselow Tucker Achin Gupta healthcare access diabetes care obesity care